Bacillaene-Producing Bacteria for Pathogen Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current probiotics in the feed industry primarily focus on maintaining gut health but lack effectiveness against specific pathogenic bacteria, such as Clostridium perfringens, Vibrio parahaemolyticus, and Salmonella, which cause diseases in animals and humans.
Innovation Solution
Bacillaene-producing bacteria, specifically Bacillus amyloliquefaciens DSM 33014, are used as probiotics that inhibit the growth of these pathogens, offering bile resistance, heat resistance, and anaerobic growth capabilities, and can be administered in feed or food products to enhance animal health and treat bacterial diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional probiotics are used to maintain gut health, then gut microflora balance is improved, but effectiveness against specific pathogenic bacteria (Clostridium perfringens, Vibrio parahaemolyticus, Salmonella) is insufficient
Solution Approach 1:
The patent changes the chemical parameter of the probiotic by introducing bacillaene, a polyene macrolide antibiotic produced by Bacillus subtilis. This chemical modification enables the probiotic to specifically target and inhibit pathogenic bacteria (Clostridium perfringens, Vibrio parahaemolyticus, Salmonella) while maintaining gut health benefits, thus resolving the contradiction between reliability against pathogens and broad adaptability.
2Reliability
If antibiotic growth promotors are used to suppress pathogenic bacteria, then pathogen growth is inhibited, but the need for probiotics to fulfill additional functions (digestion help, gut health) becomes redundant
Solution Approach 1:
The patent creates a multi-functional probiotic system where Bacillus subtilis performs multiple roles: (1) produces bacillaene to suppress pathogenic bacteria, (2) maintains gut health by influencing gut microflora positively, and (3) provides digestive assistance through bacterial enzymes. This single probiotic agent replaces the need for separate antibiotic growth promotors and functional probiotics, resolving the contradiction between pathogen suppression and versatility.
3Reliability
If bacillaene-producing bacteria are used as probiotics, then pathogenic bacteria growth is inhibited, but the complexity of ensuring bile resistance, heat resistance, and anaerobic growth capabilities increases
Solution Approach 1:
The patent employs Bacillus subtilis, a naturally occurring bacterium that inherently produces bacillaene and possesses self-contained mechanisms for bile resistance, heat resistance, and anaerobic growth capability. The bacterium serves itself by naturally having these survival mechanisms built-in, eliminating the need for complex external interventions or modifications to meet probiotic requirements, thus resolving the contradiction between effectiveness and complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of bacillaene-producing bacteria effectively reduces pathogenic bacteria populations, improves animal health, and maintains a healthy gut microflora, reducing disease incidence and improving feed conversion rates and immune responses.
Implementation Method 1
bacillaene is a secondary metabolite belonging to the class of polyenes, which was discovered and isolated from fermentation broths of a strain of Bacillus subtilis
Implementation Method 2
bacillaene is able to effectively inhibit the growth of commercially relevant pathogens like in particular toxin producing Clostridium perfringens
Data Source
AI summary
Bacillaene producing bacteria and compositions containing bacillaene producing bacteria can be used as probiotic feed ingredients. Bacillaene or derivatives thereof can be used for treating bacterial diseases.